GlassScriptPhysician profile
Helda Bacall
NPI 1134731466
$9,043.47
in general payments reported to CMS, 2019-2025
17 companies · $5,525 in 2025
The $5,525 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $453 · 2023: $526 · 2024: $2,212 · 2025: $5,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,250 · Food and Beverage: $1,502 · Education: $726 · Travel and Lodging: $622 · Honoraria: $600 · Consulting Fee: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,250.00 |
| Food and Beverage | $1,502.48 |
| Education | $726.18 |
| Travel and Lodging | $621.87 |
| Honoraria | $600.00 |
| Consulting Fee | $562.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,181.43 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $579.22 | 2024-2025 | Akeega, Erleada |
| Astellas Pharma US INC | $375.04 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $340.82 | 2021-2024 | Lynparza |
| Seagen INC. | $308.46 | 2022-2025 | Padcev |
| Exelixis INC. | $289.80 | 2024-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $191.39 | 2024-2025 | |
| Daiichi Sankyo INC. | $154.60 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.17 | 2023-2024 | |
| Gilead Sciences, INC. | $119.60 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $91.63 | 2023-2025 | Rybrevant, Erleada |
| Sumitomo Pharma America, INC. | $72.91 | 2023-2025 | Orgovyx |
| Astellas Pharma Global Development | $69.73 | 2023-2025 | Xtandi, Padcev |
| Eisai INC. | $49.19 | 2024 | |
| Emd Serono, INC. | $24.32 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.75 | 2024 | |
| Myovant Sciences INC. | $19.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helda Bacall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.